A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Desmetramadol (Primary) ; Tramadol
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Syntrix Biosystems
- 31 Oct 2019 According to an Syntrix Pharmaceuticals media release, positive desmetramadol trial was featured on the October 2019 cover of The Journal of Pain, the official journal of the American Pain Society.
- 04 Jun 2019 Results from this and another phase I trial (profile 289610) presented in a Syntrix Biosystems media release.
- 18 Apr 2019 Results evaluating steady-state pharmacokinetics, efficacy and safety of desmetramadol versus placebo and versus tramadol published in the Journal of Pain